Normalization of fat accrual in lipoatrophic, HIV-infected children switched from stavudine to tenofovir and from protease inhibitor to efavirenz

Alessandra Viganò, Paolo Brambilla, Laura Cafarelli, Vania Giaeomet, Simona Borgonovo, Ilaria Zamproni, Gianvincenzo Zuccotti, Stefano Mora

Research output: Contribution to journalArticlepeer-review

Abstract

Objective: An antiretroviral regimen based on lamivudine +stavudine+protease inhibitor impairs peripheral fat accrual in HIV-infected children and adolescents. We assess the effect on body composition parameters of replacing stavudine with tenofovir and protease inhibitor with efavirenz in paediatric patients. Methods: A 96-week prospective study on 24 patients, (age range: 5.0-17.9 years) with stable undetectable HIV-1 loads, who were switched from stavudine to tenofovir and from protease inhibitor to efavirenz. Patient assessment included: body composition parameters measured by dual-energy X-ray absorptiometry (DXA), viral load and CD4+ T-count and percentage. As a control group for DXA data, we studied 143 healthy controls (HCs; age range: 4.9-20.0 years). Results: Virological suppression and unchanged CD4+ T-cell count and percentage were maintained in all patients. At baseline, patients showed decreased total, arm and leg fat masses (P

Original languageEnglish
Pages (from-to)297-302
Number of pages6
JournalAntiviral Therapy
Volume12
Issue number3
Publication statusPublished - 2007

ASJC Scopus subject areas

  • Pharmacology

Fingerprint Dive into the research topics of 'Normalization of fat accrual in lipoatrophic, HIV-infected children switched from stavudine to tenofovir and from protease inhibitor to efavirenz'. Together they form a unique fingerprint.

Cite this